New Zealand markets open in 9 hours 40 minutes

NAMS Aug 2024 30.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.65000.0000 (0.00%)
As of 09:30AM EDT. Market open.
Full screen
Previous close1.6500
OpenN/A
Bid0.0000
Ask0.0000
Strike30.00
Expiry date2024-08-16
Day's range1.6500 - 1.6500
Contract rangeN/A
VolumeN/A
Open interest1
  • GlobeNewswire

    NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office

    -- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerat

  • GlobeNewswire

    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NAARDEN, the Netherlands and MIAMI, June 07, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s

  • GlobeNewswire

    NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June

    NAARDEN, the Netherlands and MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the fo